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Abstract
The most common presenting complaint to the emergency department (emergency room)
is pain. Unfortunately, pain is still undertreated in this setting. Literature has shown that
treatment of pain not only improves patient satisfaction but also improves mood, decreases
length of hospital stay, and decreases mortality. Various pharmacological options are
available for treating acute pain, ranging from oral, intravenous, and intramuscular
medications; topical agents; and peripheral nerve blocks. Objectively assessing and
documenting a patient’s pain is the key to determining treatment. The approach to a
patient with acute pain requires an experienced clinician who is aware of the pharma‐
cology  of  analgesics  and  anesthetics,  contraindications,  precautions,  side  effects,
administration methods, and monitoring requirements.
This chapter briefly covers the pathophysiology of acute pain and the different treat‐
ment modalities available to the emergency physician.
Keywords: pain, acute, emergency, treatment, management
1. Introduction
1.1. Epidemiology
The most common presenting complaint to the emergency department (ED) room is pain. From
1996 to 2015, ED visits have risen over 46%, from 90.3 million to [1] 136 million [1, 2]. As
emergency room visits continue to grow every year, so does the need to treat patients in pain.
Roughly, 45% of ED visits involves either moderate or severe pain [3]. The most common pain-
related chief complaints in descending order are chest pain, back pain, and headache. Fur‐
thermore, the most frequently ordered analgesics, both in the ED and at discharge, are
acetaminophen (alone or in combination with hydrocodone), ketorolac, and ibuprofen [3].
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
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and reproduction in any medium, provided the original work is properly cited.
1.2. Oligoanalgesia
Despite the trend in increasing ED visits of which the majority involves pain, pain is still
undertreated in the ED. Oligoanalgesia is a term used to describe the inadequate treatment of
pain and was first studied in a retrospective chart analysis in 1989 by Wilson and Pendleton
[4]. In this study, a total of 198 patients were evaluated, and of those who received analgesics,
32% received less than optimal doses [5]. An additional retrospective study, done a few years
later, revealed that only 30% of 401 patients treated for bone fractures received analgesics [6].
In a separate study, patients were surveyed after treatment in a fast-track area of the emergency
room, and 60% of patients went home with more pain than they were willing to accept [7].
More recently, a prospective, multicenter study enrolled 842 patients (aged 8 years and older)
across 20 US and Canadian EDs with presenting pain intensity scores of 4 or greater on an 11-
point numerical rating scale and found that only 60% of patients received analgesics, and 74%
of patients were discharged in moderate to severe pain. Furthermore, reassessments were
uncommon, and analgesics were administered after lengthy delays (median, 90 minutes;
range, 0–962 minutes) [8].
1.3. Why is treating pain important?
The Joint Commission on Accreditation of Hospitals Organization (JCAHO) has recommended
that assessment and treatment of pain be improved. Moreover, patients expect to have their
pain treated fairly quickly and to have it significantly reduced. Studies have shown that
patients want their pain treated in less than half an hour, yet the mean time of treatment is at
least 78 minutes [9]. Acknowledging and treating pain in the ED improves the rapport between
physician and patient. Patients are more likely to characterize physicians who treat their pain
as warm and friendly and inspire more confidence to discuss their private health concerns [10].
Inadequately treating pain can contribute to the development of comorbidities such as
depression, hypertension, and immune system dysfunction [10].
There are numerous potential reasons for which pain is inadequately treated in the ED, such
as concern of masking symptoms, poor communication between clinician and patient (lan‐
guage, cultural), lack of documentation and reassessment of pain, and fear of contributing to
and causing addiction. One of the most cited reasons is the concern that analgesics, particularly
opioids, may mask symptoms of a surgical abdomen. This concern has been refuted by a
number of studies. A randomized double-controlled trial conducted in 2002 evaluated pain
control in the diagnosis of appendicitis. Pain was adequately treated, and patients continued
to have pain upon palpation on physical examination [11]. An additional study studied the
surgeon’s confidence in physical signs after administration of morphine to patients with
appendicitis. Despite the morphine, these surgeons continued to illicit examination signs such
as the obturator sign, Rovsing, and pain upon jumping [12]. Other physicians may argue that
opioids may mask the intensity of pain allowing for the progression of the illness to compli‐
cations such as perforation and formation of an intra-abdominal abscess. A systematic review
of six randomized controlled trials evaluating the safety of opioid administration to children
with acute abdominal pain showed no significant difference in the rate of perforation or abscess
formation [13]
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The concern over causing addiction plays an important role in oligoanalgesia in the ED. In
2012, health care providers wrote 259 million prescriptions for painkillers. This is equivalent
to every American adult having a bottle of pills. Furthermore, each day, 46 people die from an
overdose of prescription painkillers in the United States [14].
In 2007 the cost of prescription opioid abuse was estimate to be $56 billion dollars [15]. Those
with a prior history of depression, anxiety, and substance use were most likely to have a
propensity for prescription opioid abuse [16]. An additional study confirmed mental disease
as risk factor for opioid abuse, as well as males, younger adults, and individuals with greater
days of supply of prescription opioid abuse. Thus, the emergency physician must do a full
history, including a psychiatric history, prior to considering opioids.
Screening programs not only elucidate a patient’s past-filled prescriptions but can also give
the physician an idea of the different pharmacies and health clinics the patient has gone to.
This information gives the prescriber insight into any drug-seeking behavior and may change
their propensity into prescribing a certain analgesic [17].
1.4. Documentation of pain
The effective management of acute pain in the ED requires appropriate assessment of the pain
based on the patient’s perception of pain using a validated pain scale. Additionally, reassess‐
ment of pain is essential to determine the effect of treatment. Pain has been described as a vital
sign, and as such it should be documented in the initial assessment of a patient. Verbal pain
scores (VPSs) may reveal those who are truly in pain but who may not voice their discomfort,
as well as influence the physician to inquire about the patient’s pain. One study revealed, that
in patients who did not receive analgesics, 42% desired them, but only 31% voiced their concern
[8]. A prospective study introducing VPSs in an ED revealed that of those trauma patients who
had VPS scores documented, 60% received analgesics versus 33% in those who did not have
a VPS score documented. Furthermore, those with higher VPS scores were more likely to
receive analgesics [18]. ED crowding has been shown to increase time to analgesic adminis‐
tration and mortality [19]. The use of VPS in this setting may identify those individuals in need
of quicker treatment.
2. Pathophysiology
Pain can be divided into acute and chronic, with acute pain being incited by a traumatic injury
or pathologic condition. As the causative issue is addressed, acute pain is usually resolved.
Acute pain is mediated through nociceptors, of which there are various types ranging from
mechanical to thermoreceptors. These receptors are stimulated by chemical, thermal, or
mechanical stimuli [20]. As these receptors are stimulated, sensory neurons transmit the
stimulus through neuronal pathways made up of various peripheral nerve fibers. “First Pain,”
which is well localized and sharp, is modulated by Aδ-fibers. The second component of pain,
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or the slow phase, is conducted by C fibers and is characterized by dull and poorly localized
pain [21].
All pain starts as acute pain; however, not all pain progresses to chronic pain. Acute pain
becomes chronic when pain persists despite the resolution of the inciting event. There may be
many causative factors that account for prolonged pain. Apart from the psychosocial influen‐
ces on chronic pain development, physiologic factors that contribute to chronic pain include
alterations in the spinal cord that occur when acute pain is inadequately treated. These changes
lead to increased excitability, decreased inhibition, and reorganization of certain spinal tracts
[22]. The time frame for defining chronic pain varies from 3 to 6 months of ongoing pain.
However, some would argue that chronic pain is any pain that persists longer than the
reasonably expected healing time for the involved tissues. It is also important to understand
that an individual’s perception of pain may be influenced by culture, previous painful
experiences, beliefs, mood, and ability to cope.
2.1. Somatic and visceral pain
Somatic pain is made up of mostly A-fibers and is located in cutaneous tissues as well as deep
tissues such as fascia, tendons, or bone. This pain is described as initially sharp and then as
burning or throbbing. On the contrary, visceral pain is primarily composed of C f-fibers, and
its primary afferent neuron endings are usually found in internal organs such as intestines,
gonads, or heart [21]. For example, at presentation, pain from appendicitis may initially be
poorly localized around the periumbilical site and characterized as dull, indicating primarily
a visceral pain. However, as inflammation continues, the above fascia tissues become inflamed.
At this point, pain is now located at the right lower quadrant and may be sharp. This later
presentation of appendicitis is now primarily involving the somatic cutaneous nerves in the
corresponding dermatome. Asking the patient to initially describe the pain may hint toward
the initial causative pathologic condition. For instance, in a patient with sharp and clearly
localized back pain, the causative agent may be musculoskeletal in nature. However, those
with dull, achy, and poorly localized pain, back pain radiating to the groin may be due to an
internal cause such as pyelonephritis or nephrolithiasis.
2.2. Neuronal pathway
The initiating stimulus of pain is conducted through these peripheral nerve fibers. There are
a number of neuronal pathways through neuronal pathways, but the spinothalamic tract is
the main pathway. These pathways converge into primary afferent neurons found in the dorsal
root ganglion. Afferent neurons have two endings: one signaling the peripheral system and
the second signaling second-order neurons in the dorsal horn. The second-order neurons’
axons cross the midline of the spinal cord into the contralateral spinothalamic tract, where they
ascend into the thalamus. Third-order neurons in the thalamus synapse with the second-order
neurons and send signals to the post-central gyrus of the cerebral cortex [21]. As the nerve
fibers ascend in the spinal cord, they organize into dorsolateral columns and anteromedial
segments [20].
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The dorsal columns and anterior medial segment are divided into different segments called
laminae. This is done to organize the type of sensory information sent into each section [23].
Laminae 1 through 6 are located in the dorsal horn, 7 through 10 in the intermediate zone, and
8 though 9 in the anterior/ventral horn. The gray matter surrounding the central cord composes
lamina 10. All afferent nerve activity is received in the dorsal horn. Specifically, lamina 1
receives mostly noxious stimuli from cutaneous tissues and deep somatic tissues. Visceral
afferent fibers are transmitted to laminas 5 and 1. However, lamina 5 also receives somatic
afferent fibers, and it is this convergence that leads to referred pain [21]. Lamina 2, or the
substantia gelatinosa of Rolando, mediates the activity of pain and temperature afferent fibers.
Next, lamina 3 and 4, known as the nucleus proprius, receive input from lamina 2 and also
help regulate pain, temperature, as well as crude touch. Lamina 7 receives afferent input from
muscle fibers and joints [24].
Furthermore, the spinothalamic tract is subdivided into a lateral and a medial tract. The lateral
tract projects to the ventral posterolateral nucleus of the thalamus and carries fibers sensory
input that transmits location, intensity, and duration of pain. The medial tract projects to the
medial nucleus of the thalamus and mediates the emotional and autonomic aspects of pain.
Collateral fibers from the spinothalamic tract are also projected to the RAS, or reticular
activating system, as well as the hypothalamus [21]. These collateral fibers may be responsible
for the arousal aspect of pain.
2.3. Modulation of pain
Descending tracts originating from the midbrain and medulla feed into the spinal cord through
the dorsolateral funiculus, modulating pain [20]. For example, stimulation of the periaque‐
ductal gray, through projections from the spinothalamic tract, provides widespread analgesia
in humans [25, 26]. One investigator noted that stimulation of the periaqueductal gray leads
to analgesia with such significance that one could perform an exploratory laparotomy without
any chemical anesthesia [26, 27]. Furthermore, these tracts involve transmitters such as
norepinephrine, serotonin, and opiates [20]. TCAs and SSRIs through these neurotransmitters
have been shown in various studies to significantly reduce chronic pain, regardless of the
patient’s psychosocial status. A meta-analysis found there is no difference in pain relief from
the use of these medications in the absence or presence of depression, and the size of analgesia
is not significantly different in the presence or absence of anti-depressant effect [28].
Additional modulation of pain can be seen through the endorphin system. This system consists
of neurons that secrete three types of opioids beta-endorphin, net- and leu-enkaphalins, and
dynorphins. These chemicals act on the mu, delta, and kappa receptors modulating pain relief
[20].
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3. Common analgesic agents used in the emergency department
3.1. Opioids
Opioid prescriptions for the management of non-cancer pain have increased over the last 10–
20 years. Concerns of opioid dependence and toxicity, such as respiratory depression, have
led to the under-dosing of these agents in the ED and the use of other less effective analgesic
agents.
3.1.1. Mechanism
The term opioid refers to natural and synthetic substances that act at one of the three main
opioid receptor systems (mu, kappa, delta). They can have analgesic and central nervous
system (CNS) depressant effects as well as the potential to cause euphoria. The majority of
opioids used clinically target μ-opioid (mu) receptors. These receptors mediate analgesia as
well as common side effects such as euphoria, constipation, and respiratory depression [29].
One exception is the combination of agonist–antagonist agents such as buprenorphine.
Another less commonly targeted receptor is the κ-opioid (kappa) receptor, which is important
in regulating GI motility and dysphoria. The other endorphin receptors may regulate neuro‐
pathic pain, as we all as spinal anesthesia.
3.1.2. Morphine
One of the most commonly used opioids in the ED is morphine. It is considered safe and
effective in the monitored setting in the ED [29].
Side effects can range from hypotension, pruritus, nausea, vomiting, and respiratory depres‐
sion. It is believed that some of these side effects may be due to the destabilization of mast cells
that lead to the release of histamine. Respiratory depression is caused by desensitization of the
medulla to carbon dioxide, through opioids binding to the mu receptor. The cardiovascular
effects of opioids are mediated centrally at the central vagal nucleus and, in the case of
morphine, directly into the sinoatrial node. Within the gastrointestinal system, opioids delay
gastric emptying and cause constipation [29]. There appears to be no significant differences in
side effects between dosages of 0.1 mg/kg and 0.15 mg/kg.
Weight-based dosing for morphine is not necessary in obese patients. A prospective observa‐
tional study in the ED revealed that patient’s weight was not predictive of pain reduction [30].
Thus one should start with the recommended dose of 0.1 mg/kg if side effects are of concern;
however, one should be ready to rebolus in 5–15 minutes as studies have revealed this initial
dosing is inadequate. A prospective cohort study of 119 patients revealed that 67% of patients
who received 0.1 mg/kg of morphine stated less than 50% reduction of pain 30 minutes later
[31]. A later study evaluating trauma patients revealed that a dose of 0.15 mg/kg when
compared to 0.1 mg/kg significantly reduces pain without any significant difference in adverse
events [32].
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In the setting of trauma, hypotension may reduce tissue perfusion in patients with significant
blood loss. However, in a randomized controlled study in acute trauma patients, hypotension
only occurred in 10% of patients who received morphine [32]. A study investigating the use
of morphine in the pre-hospital setting in ST segment elevation myocardial infarction patients
found no worsening of in-hospital complications or 1-year mortality [33]. The cancer literature
has also shown the value and safety of morphine infusions for pain control [34].
3.1.3. Hydromorphone
Hydromorphone is a semisynthetic derivative of morphine that is seven times more potent
than morphine. Despite the increased potency, studies have shown that nurses who are
concerned about side effects may give a lower dose of morphine versus hydromorphone since
the “total milligrams” given in hydromorphone is less when compared to an equal analgesic
dose of morphine [35]. Despite the dosing difference, hydromorphone appears to offer better
pain control. In a retrospective study involving the use of patient-controlled analgesia (PCA)
with either morphine or hydromorphone, more patients receiving morphine required rescue
analgesia due to initial inadequate pain control [36].
Pruritus occurs less frequently with hydromorphone. Hydromorphone is conjugated by the
liver to hydromorphone-3-glucoronide, an inactive metabolite. However, morphine’s metab‐
olite is active, and as a result, hydromorphone is better tolerated [20]. With regard to adverse
effects, hydromorphone has not been shown to have an increased risk, and its use does not
necessitate increased naloxone administration [37].
3.1.4. Fentanyl
When pain relief is needed quickly for acute severe pain, such as in trauma, fentanyl may be
of use. Its time of onset is 1–2 minutes and lasts typically about 30 minutes [20]. The initial IV
dose is 1.5 μg/kg, and it has the advantage of a short half-life. This is particularly useful if serial
examinations are needed. Fentanyl causes minimal histamine release, making it ideal in
patients in whom blood pressure must be maintained. For example, in severe traumatic brain
injury patients, in whom MAP must be kept above 80 to maintain cerebral perfusion pressure,
and must be examined serially, fentanyl may be a useful analgesic. The safety profile is
favorable, particularly in the pre-hospital setting. A retrospective chart review of 2,129 patients
transported by Emergency Medical Services revealed that fentanyl affected vital signs in less
than 1% of patients [38]. Despite its favorable hemodynamic profile, fentanyl may cause chest
wall rigidity when given in doses above 15 μg/ kg leading to inadequate ventilation. This is a
rare complication and can be remedied through neuromuscular blockade or naloxone [39, 40].
3.2. Non-opioid medications
Non-opioid analgesics include acetaminophen, non-selective nonsteroidal anti-inflammatory
drugs (NSAIDs), and cyclooxygenase 2 (COX-2) inhibitors. NSAIDs and COX 2 inhibitors have
anti-inflammatory properties.
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3.2.1. Acetaminophen
A common over-the-counter analgesic for mild to moderate pain is acetaminophen (para-
acetylaminophenol) or paracetamol (in Europe). Its mechanism of action is through the
inhibition of prostaglandin endoperoxide H2 synthase and cyclooxygenase activity [20, 41]. Its
central anti-pyretic effect is of great use when fever needs to be reduced. It has been shown to
have good analgesic effects; however, acetaminophen is not anti-inflammatory. Systematic
reviews have shown that acetaminophen can significantly reduce pain; however, it may be
less effective than NSAIDs in conditions such as back pain and osteoarthritis [42–44]. Acet‐
aminophen can also be combined with opioid medications to reduce the amount of opioid
needed. However, concerns about unintentional acetaminophen overdose have led to combi‐
nation drug products with more than 325 mg acetaminophen per tablet to be withdrawn from
the market. Acetaminophen overdose can lead to severe hepatotoxicity and should be used
cautiously in patients with chronic alcohol use or liver disease.
Intravenous acetaminophen is being studied for acute pain such as in acute traumatic limb
injuries [45] or rib fractures [46] or in postoperative patients [47, 48]. It has also been shown to
reduce the need for rescue pain medications such as opioids [49, 50].
3.2.2. Nonsteroidal anti-inflammatory drugs
NSAIDs provide analgesia for mild to moderate pain and also work synergistically when
paired with opioids. They work through the inhibition of cyclooxygenase by decreasing the
production of prostaglandins and prostacyclins, primarily cyclooxygenase 1 (COX-1) and
COX-2. COX-1 mediates platelet aggregation and maintenance of gastrointestinal mucosal
integrity. By contrast, COX-2 generates prostaglandins that mediate pain and inflammation
[29]. The different NSAIDs can be either selective COX-2 inhibitors or non-selective, thus
differing in their side-effect profile. There are many NSAIDs to choose from, but there is little
literature showing improved efficacy of one NSAID over another.
Main adverse side effects of NSAIDs include gastrointestinal insult, renal insult, inhibition of
platelets, cardiovascular effects, and anaphylaxis. Renal failure is caused by the decreased
production of prostaglandins, which aid in afferent glomerular arteriole vasodilation. NSAIDs
contribute to arteriolar vasoconstriction, leading to decreased renal perfusion pressure and
decreased glomerular filtration rates [51]. This is worsened by dehydration. As selectivity of
COX inhibition increases, the renal effects decrease. NSAIDs such as ketorolac and diclofenac
have fewer effects on the kidney than naproxen or ibuprofen [51, 52].
The most common side effect of NSAIDs is gastrointestinal injury, such as bleeding or
dyspepsia and gastric ulceration. Patients who are at high risk for peptic ulcer disease or its
complications, such as the elderly, those with bleeding diathesis, or patients on glucocorti‐
coids, have a relative contraindication to the use of an NSAID. Each NSAID has variability in
the risk of gastrointestinal injury it poses. This is due to the selectivity of COX-1 inhibition, so
that the relative risk of for ibuprofen is 2.6, while the relative risk for ketorolac is 14.5 [51, 53].
Various studies have shown that COX-2 inhibition is related to increased cardiovascular risk.
This is believed to be the result of decreased prostacyclin (prostaglandin I2) and increased
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thromboxane A2. The effects lead to hypertension, accelerated atherogenesis, and increased
thrombotic response to plaque rupture [54]. Myocardial infarction was found to be increased
in this class of NSAIDs, resulting in the discontinuation of rofecoxib [55, 56]. Furthermore, it
has been shown that specific COX-2 inhibitors may also further inhibit renal perfusion and
lead to decreased sodium excretion, which may further worsen congestive heart failure and
renal function [57, 58]. Due to COX-2 specific inhibitor side-effect profile and no proven
increased efficacy over non-selective NSAIDs, there is minimal to no advantage in using this
class in the ED.
There has been no proven efficacy over one type of NSAID, including the route of adminis‐
tration such as intra-muscular versus oral [29, 59, 60]. One should select a particular NSAID
based on its side-effect profile and the route of administration that is the most feasible for the
patient. Furthermore, prior to using NSAIDs, one must also take into consideration that this
class of pharmaceuticals is most useful when used in pain mediated by prostaglandins or
inflammation, not in other situations such as neuropathic pain. For instance, NSAID, partic‐
ularly ketorolac, has been shown to significantly reduce pain in renal colic, and has similar
efficacy in pain reduction as morphine [61]. When used in combination, opiates and NSAIDs
may reduce the need of additional doses of analgesic rescue therapy in renal colic and have
greater pain efficacy than either drug used alone [62]. In acute lower back pain, NSAIDs have
been shown to significantly reduce pain and improve daily function [63]. The addition of
opioids in this setting of pain was not proven to be more effective than NSAIDs alone [64].
3.2.3. Antispasmotics (muscle relaxants)
Muscle relaxants have been used by the physicians with the intention of alleviating muscu‐
loskeletal pain. However, data on this class of medications have produced mixed results since
their action may be more the result of sedation rather than muscle relaxation. A systematic
review, evaluating the effectiveness of cyclobenzaprine in lower back pain, revealed short-
term improvement of pain at 7 days. However, there was no improvement of pain at 14 days,
and there was no statistical difference when compared to diazepam [65]. Furthermore, in a
second review evaluating the effectiveness of muscle relaxants in neck pain, there was no
difference when compared to placebo at 2 weeks [66].
When compared to NSAIDs, muscle relaxants have been shown to have no significant
difference in pain relief or improvement in daily function. Moreover, there is little to no added
benefit when using muscle relaxants together with NSAIDs [64, 67]. Given the limited data on
muscle relaxants, one should consider the side effects. Major side effects range from
drowsiness, dizziness, dry mouth as well as other anticholinergic effects. These medications
should only be prescribed for short-term use, given the limited data regarding efficacy past 1
week. In addition, one should refrain from prescribing these medications in the elderly, as they
are at higher risk of falls and delirium.
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3.2.4. Topical analgesics
There are various topical agents ranging from patches, gel, sprays to creams, which may aid
in relieving pain. They appear to have several potential advantages over systemic drugs such
as delivery at the site of injury, lower levels of systemic absorption, and fewer systemic effects.
Although systemic side effects are not as frequent as oral formulations, significant systemic
concentration can be achieved by topical application.
Often, these agents have similar efficacy to their oral preparations. For example, a randomized
controlled trial comparing a gel preparation of ibuprofen versus oral tablets revealed compa‐
rable improvement in patient’s pain and functional status at 2 weeks [68]. Topical agents often
have fewer side effects than their oral counterparts, and most adverse events are primarily
cutaneous in nature such as rashes or pruritus. Decreased adverse events may be due to lower
bioavailability in the plasma [69, 70]. Many factors may influence the penetration of the topical
agent into the local site. Variability in an individual’s skin properties such as the thickness of
stratum corneum may be a limiting factor. Furthermore, the agent must be lipophilic and
water-soluble [71]. Local site pH, such as acidity in a local cellulitis, may also limit penetration
of the agent.
Topical NSAIDs have been shown to have rare incidences of gastrointestinal adverse events
such as ulcer formation, as opposed to oral formulations [69]. Topical diclofenac and ibuprofen
have been shown to be effective in acute soft tissue injuries, such as ankle sprains as well as
arthritic knee pain [68, 72, 73]. Furthermore, topical diclofenac has been shown to be effective
in reducing myofascial pain, however, with no effect on the myofascial trigger point pain
threshold [74]. Topical NSAIDs have been shown to have equal efficacy as oral NSAIDs, yet
various studies have shown topical diclofenac to reduce pain within 2–3 days of treatment [72,
75–77].
Neuropathic pain has been shown to respond to topical agents. For example, topical lidocaine,
when used in post-herpetic neuralgia (PHN), has been associated with improved quality of
life, improvement of pain and allodynia [78]. Moreover, when compared with oral pregabalin,
response rates were higher in patients with either PHN or diabetic neuropathy. The same
studies also showed a lower rate of adverse events and improved quality of life [77, 79, 80].
Topical capsaicin cream has also been studied to reduce neuropathic pain; nonetheless,
application of this cream has been associated with a burning sensation in up to 81% of patients
[81]. Randomized controlled studies of high concentration topical capsaicin revealed signifi‐
cant pain relief in patients with PHN with relief lasting up to 12 weeks [77, 82, 83].
Topical opioids have not been shown to significantly reduce pain. For example, a randomized
controlled trial comparing the use of topical morphine sulfate versus traditional Jelonet
dressings in burn patients revealed increased need of rescue analgesia and higher pain scores
in the topical morphine group [84]. Another study revealed no significant reduction in pain
with patients with skin ulcers when topical morphine was compared to placebo [85]. However,
in patients with mucositis undergoing chemoradiotherapy for head and neck cancer, oral
morphine mouthwash has been shown to significantly reduce pain and reduce length of
functional impairment [86]
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In summary, topical analgesics may provide additional analgesia in patients who may not be
able to tolerate the adverse effects of systemic analgesics. Those with PHN may benefit from
topical lidocaine when amitriptyline fails to provide relief. Those with peptic ulcer disease
may benefit from topical NSAIDs to treat arthritis, as oral NSAIDs may worsen their condition.
By contrast, topical opioids have not been shown to provide significant relief in burns or skin
conditions, limiting their role in the ED.
3.3. Peripheral nerve blocks
There are two types of nerve blocks: single injection and continuous nerve blocks.
Single-injection nerve blocks are one-time injections of local anesthetic adjacent to the nerve
or plexus for anesthesia and/or analgesia and are most commonly used in the ED. Continuous
infusion nerve blocks involve the placement of catheter adjacent to the peripheral nerve or
plexus. These are useful in patients who are expected to have prolonged need for analgesia.
The effectiveness and duration of the block depend upon the pharmacology of the analgesic/
anesthetic agent used, the dose, and the concentration.
Peripheral nerve blocks are important tools for pain management in the ED and have been
shown to significantly reduce pain. Analgesia from peripheral nerve blocks can be reached
more quickly than intravenous narcotics and often with more efficacy and less rescue analge‐
sics. A randomized controlled trial compared the use of femoral nerve blocks versus intrave‐
nous narcotics in femoral fractures and found lower pain scores within 90 minutes in the
femoral nerve block group. The incidence of infections was the same in both groups, and there
were no reports of paresthesias [87]. In fact, the total amount of morphine required to produce
adequate analgesia was up to three times higher in intravenous narcotics group than in patients
with a peripheral nerve block [88].
The benefits of peripheral nerve blocks have not only been seen in femoral fractures but also
in other traumatic injuries such as hand lacerations, upper extremity fractures, and disloca‐
tions. For reduction of forearm fractures, studies have shown that children have less distress
and pain when a brachial plexus block was performed versus procedural sedation [89].
Furthermore, length of stay in the ED was also significantly reduced when brachial plexus
block was performed with length of stay being reduced almost 3 hours [90]. Similarly, patients
with shoulder dislocation that underwent a brachial plexus block also showed reduction in
ED length of stay, without any increased adverse events or reduction in patient satisfaction
[91].
One of the most concerning complications of peripheral nerve blocks is nerve damage. In a
peripheral nerve block, the goal is to position the local anesthetic around the nerve and not
“into” the nerve. One should avoid intra-neural injection that may cause direct trauma or
toxicity to the nerve. The incidence of nerve damage in the days following the block (including
temporary paresthesias) ranges from 0.5 to 15% [92, 93]. However, in significant nerve damage
resulting in peripheral neuropathy or symptoms lasting longer than 6 months, incidence was
reported to be less than 0.1% in a prospective study [92, 94]. Most complications of nerve
damage are transient, with most patients recovering by 3 weeks. Localized infection has been
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noted to be rare, with 3% of peripheral nerve catheters in anesthesia studies showing signs of
infection or abscess formation [95]. On the contrary, vascular puncture is not uncommon, and
incidences of up to 5.7% and 6.6% have been noted when investigators placed femoral or sciatic
nerve peripheral catheters [92, 96]. Systemic toxicity, such as cardiac arrest, was found to be
rare, with all cases of cardiac arrest noted to be in central spinal anesthesia. Additionally,
seizures were noted in 6 out of 50,223 cases [94].
Ultrasound and nerve stimulator techniques have been shown to reduce the complications
from peripheral nerve blocks. One study investigating the use of ultrasound or electrical
stimulation in the placement of a brachial plexus peripheral nerve catheter resulted not only
in decreased time performing the procedure but also no vascular punctures in the ultrasound-
guided group [97]. Furthermore, a Cochrane systematic review also confirmed faster proce‐
dure times and reduced local anesthetic volume and improved quality of nerve block [98].
Emergency physicians are adept at using ultrasound in central line placement, as well as in
other diagnostic procedures, such as in FAST abdominal examinations, in trauma patients.
Emergency physicians can be trained in ultrasound-guided peripheral nerve blocks as well.
Ultrasound imaging permits direct visualization of needle location relative to target nerves,
blood vessels, and related structures, as well as observation of the local anesthetic during and
after the injection. A prospective observational study trained emergency physicians in the use
of ultrasound guided peripheral nerve blocks in patients with traumatic limb emergencies and
found that trained physicians were able to perform the ultrasound-guided nerve blocks in
about 9 minutes with no complications and no need of rescue procedural sedation [99].
Prior to the decision to perform a peripheral nerve block, a careful medical history should be
obtained including allergies, use of anticoagulants, preexisting nerve damage, active infections
at the site, and ability to cooperate with the procedures. During the placement of peripheral
nerve bocks, patients should be carefully monitored. It is important to assess for preexisting
sensory or motor deficits in the distribution of the block. A patient with neurologic deficits
prior to the nerve block may be at higher risk for developing new neurologic deficits following
a nerve block than a patient without preexisting deficits. A brief overview of the femoral and
brachial plexus peripheral nerve will be explained in the section below.
3.4. Femoral nerve block
The femoral nerve block is used to anesthetize the hip, anterior thigh, and knee. This nerve
passes beneath the inguinal ligament and travels lateral to the femoral artery within the
femoral triangle (Figure 1) [100]. The fascia iliaca separates the femoral nerve from the femoral
vascular bundle [101]. The patient is initially positioned in a supine position. The affected
extremity is then externally rotated and abducted. With the probe marker to the patient’s right,
a linear probe is then placed at the inguinal crease parallel to the inguinal ligament, the femoral
nerve will then be visualized (it may appear as a hyper echoic, honeycombed structure).
Medially, the femoral artery and then the femoral vein will be present. The iliopsoas muscle
will be present posteriorly and the fascia lata superiorly (Figure 2) [101, 102].
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Figure 1. Femoral triangle.
Figure 2. Placement of the ultrasound linear probe for the femoral nerve block. The patient is laid in a supine position
with the affected extremity externally rotated and abducted. The linear probe is placed in a transverse fashion inferior‐
ly to the inguinal crease.
Once the structures and anatomical landmarks mentioned above have been identified, aseptic
skin preparation is performed and anatomic structures at the block site are again identified
using an ultrasound probe in a sterile plastic sheath with sterile conductive gel (Figure 3). The
structures are once again confirmed on ultrasound and then a skin wheal is made with local
anesthetic. When the optimal ultrasound view is achieved, the probe is held immobile; the
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block needle is then inserted at the skin on the lateral edge of the probe in-plane, aiming for
the space behind the nerve. It is then advanced, with movement only when the needle tip is
seen. Often a “pop” will be felt as the fascia iliaca is penetrated with the needle. Next, aspiration
of the needle is done to confirm no vascular penetration. About 1–2 ml of local anesthetic is
injected to visualize the placement of the needle on the ultrasound screen. The anesthetic
should be seen surrounding the nerve. Once correct placement is confirmed, 10–20 ml of the
selected anesthetic is injected. It may take up to 10–20 minutes to take effect [101–103].
Figure 3. Ultrasound view of the femoral nerve. FA, femoral artery; FV, femoral vein; FN, femoral nerve.
3.5. Brachial plexus block
The brachial plexus block, or interscalene block, can be used to facilitate reduction of upper
extremity fractures, lacerations, and even reduce shoulder dislocations. Nerve roots of C5-T1
are the initial part of the brachial plexus, forming a complex configuration before they enter
the terminal nerves of the arm (Figure 4) [104]. The more proximal one blocks to the plexus,
the more proximal the anesthesia is on the arm. Nerve roots of C5-T1 form the superior, middle,
and inferior trunks of the plexus at the level of the cricoid cartilage. At this location, the plexus
is found superior and posterior to the subclavian artery, with the dome of the lung located
anteromedial to the inferior trunk. The interscalene space is the grove between the anterior
and middle scalene muscles. This is where one will find the structures mentioned above.
However, since the inferior trunk is often not included in this block, one cannot use this
procedure for injuries below the elbow [105].
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Figure 4. Brachial plexus.
Figure 5. Placement of the ultrasound linear probe for the interscalene brachial plexus block. The patient is laid in a
supine position with head turned away. The probe is then placed in a transverse fashion and used to identify the ster‐
nocleidomastoid muscle first. Next, one then sweeps posterior laterally to bring into view the interscalene groove.
The patient is initially positioned supine with the head turned 45 degrees to the contralateral
side. With a linear probe, one first identifies the sternocleidomastoid muscle (SCM), which is
located anteriorly to the carotid artery and internal jugular vein. One then sweeps posterior
laterally bringing into view the middle scalene muscle and anterior scalene muscles. This is
where the trunks of the brachial plexus may be visualized between the anterior and middle
interscalene muscles. As with peripheral nerves, these trunks may appear as hyper echoic
honeycombed structures (Figure 5) [105, 106]. Once the structures are identified, aseptic skin
preparation is performed and anatomic structures at the block site are again identified using
an ultrasound probe in a sterile plastic sheath with sterile conductive gel. A skin wheal is made
using local anesthetic. Then, in an in-plane approach, the block needle is inserted posterior-
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laterally to the probe, at an angle of 45 degrees to the skin. The needle is advanced toward the
plexus, aiming toward the space between the top and middle trunks. Next, aspiration is done
to check for any vascular puncture, and then placement is confirmed with movement of the
trunks on injection of anesthetic. Depending on the agent used, the volume of local anesthetic
is about 15–45 ml (Figure 6) [105, 106].
A second approach to the brachial plexus block is a supraclavicular block. To perform this
block, the patient is once again laid in a supine position with the head turned away from the
side being blocked. A linear probe transducer is then placed immediately superior to the
clavicle at its midpoint (Figure 7). Tilting the probe caudally will bring into view a transverse
view of the subclavian artery. Laterally to the artery, one will be able to see a collection of hypo
echoic, honeycombed structures, which is the brachial plexus. Underneath these structures,
the first rib is visible as a linear hyper echoic structure with lung underneath (Figure 8) [107,
108]. After the correct anatomy is identified, the skin is prepped in a sterile manner, and using
a sterile probe cover, this area is once again identified. A 27-gauge needle is then used to inject
the skin with 1–2 ml of local anesthetic just lateral to the probe. The block needle, 22-gauge, is
then advanced in an in-plane approach toward the brachial plexus from a lateral to medial
direction. At times one may feel a “pop” once the brachial sheath has been penetrated. One
then aspirates to confirm non-vascular penetration and injects 1–2 ml of anesthetic to view the
brachial plexus. Next, one then injects about 20–25 ml of anesthetic, until adequate spread is
seen surrounding the brachial plexus [107].
Figure 6. Interscalene view of the brachial plexus. ISG, interscalene groove with the brachial plexus present; SCM, ster‐
nocleidomastoid muscle; ASM, anterior scalene muscle; MSM, middle scalene muscle.
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Figure 7. Placement of the ultrasound linear probe for the supraclavicular brachial plexus block. The patient is placed
in a supine position or slightly seated position. The linear probe is then placed immediately superior to the clavicle at
its midpoint. Tilting the probe caudally will bring into view the subclavian artery with the brachial plexus seen lateral
to it, and the first rib and lung underneath.
Figure 8. Supraclavicular view of the brachial plexus. SA, subclavian artery; BP, brachial plexus; MSM, middle scalene
muscle.
Peripheral nerve blocks are a valuable asset to the emergency physician trained in these
procedures. These procedures reduce pain quicker than intravenous narcotics, decrease the
amount of sedation needed, and decrease ED length of stays. Peripheral nerve blocks may offer
an alternative to avoid respiratory and cardiovascular depression encountered with
procedural sedation or intravenous narcotics.
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4. Conclusion
Pain is the most common presenting complaint to the emergency room. Appropriate treatment
affects not only patient satisfaction and well-being but also patient outcomes. The choice of an
appropriate initial therapeutic strategy is dependent upon an accurate evaluation of the cause
of the pain and the type of pain syndrome. Effective management of acute pain in the ED
requires a systematic approach. First, an accurate assessment of the patient’s pain should
involve the use of validated pain scales. Second, suitable analgesics given in an acceptable time
frame are essential in the diagnosis and treatment. This should include proper monitoring for
adverse side effects. Third, pain should be reassessed and documented regularly to determine
the effect of treatment.
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